Target Research Articles

  1. Oncology Drug Discovery Is Targeting The Wrong Problem 5/21/2026

    There is a growing tension between what we measure and what ultimately matters. This disconnect raises an uncomfortable but necessary question: are we targeting the right problem?

  2. GLP-1 Receptor Agonists: Metabolism, Reward Biology, And AI-Driven Drug Discovery 5/6/2026

    For drug discovery teams, the central question is whether metabolic signaling pathways can serve as a tractable new entry point into addiction therapeutics.

  3. GLP-1 Agonists In Addiction: Rationale And Drug Development 4/24/2026

    GLP-1 receptor agonists represent a scientifically credible and potentially consequential avenue in addiction medicine.

  4. Next‑Generation Omics: Latest Insights From A Growing Field 4/8/2026

    Experts share their latest discovery and translational research using multi-omics technologies at the NextGen Omics Spatial & Data conference in Boston.

  5. Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics? 4/1/2026

    Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.

  6. The Missing Data Set In Drug Discovery: Patient Experience As Decision Data 3/30/2026

    Drug discovery has become highly effective at capturing molecular detail, yet the experience of disease remains difficult to incorporate into early scientific decisions.

  7. What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment 3/23/2026

    Insights gained from advancing ADC combination therapies in lung cancer are now shaping innovative approaches across multiple tumor types.

  8. Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery 3/19/2026

    We caught up with Melissa Murray, Ph.D., and Amy Rommel, Ph.D., to discuss tau-associated neurodegenerative diseases.

  9. Proteomics Biomarkers Beyond Blood 3/16/2026

    Effective biomarker strategies have the potential to accelerate decision-making, de-risk development, and help drive precision medicine.

  10. The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era 3/5/2026

    The alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.